Risk | Moderately High |
---|---|
Min SIP Amount | ₹500 |
Expense Ratio | 1.36% |
NAV | ₹45.80 (13 Apr 2021) |
---|---|
Fund Started | 01 Jan 2013 |
Fund Size | ₹2,332 Cr |
Name | Sector | Instrument | % Assets |
---|---|---|---|
Aurobindo Pharma Ltd. | Healthcare | Equity | 0.8% |
Aurobindo Pharma Ltd. | Healthcare | Futures | -0.2% |
HDFC Equity Savings Direct Plan Growth is a Hybrid Mutual Fund Scheme launched by HDFC Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Anil Bamboli, Vinay Kulkarni, Krishan Daga is the Current Fund Manager of HDFC Equity Savings Direct Plan Growth fund.The fund currently has an Asset Under Management(AUM) of ₹2,332 Cr and the Latest NAV as of 13 Apr 2021 is ₹45.80.
The HDFC Equity Savings Direct Plan Growth is rated Moderately High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. For units in excess of 15% of the investment, 1% will be charged for redemption within 365 days
The scheme seeks to provide capital appreciation by investing in Equity & equity related instruments, Arbitrage opportunities, and Debt & money market instruments.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.